Aprea Therapeutics Reports Positive Clinical Trial Results, Reduces Net Loss to $3.2 Million

Aprea Therapeutics reported a Q2 2025 net loss of $3.2 million, down from $3.5 million in Q2 2024. The company's WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119 showed early clinical activity in Phase 1 trials, with stable disease achieved in several patients. Aprea's cash position stands at $16.5 million, funding operations into Q2 2026. The company plans to refine dosing strategies and explore combination therapies to address unmet medical needs in cancer treatments.

Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its financial results for the second quarter ended June 30, 2025, with a net loss of $3.2 million, a decrease from $3.5 million in the same period last year. The company's cash position stands at $16.5 million, providing sufficient funding to meet its operating expenses and capital expenditure requirements into Q2 2026 [1].

Key highlights from the quarterly report include:
- Operating Loss: The operating loss for Q2 2025 was $3.4 million, down from $3.8 million in Q2 2024.
- Research and Development (R&D) Expenses: R&D expenses were $1.9 million, a decrease from $2.6 million in Q2 2024. This reduction was primarily due to lower expenses related to study start-up activities and a decrease in personnel costs.
- General and Administrative (G&A) Expenses: G&A expenses were $1.6 million, down from $1.9 million in Q2 2024, largely due to a decrease in professional fees and personnel costs.

Aprea Therapeutics also provided updates on its clinical trials:
- ACESOT-1051 Trial: The Phase 1 trial of the WEE1 inhibitor APR-1051 showed early signs of clinical activity, with three patients achieving stable disease. One patient in the 70mg cohort and two in the 100mg cohort demonstrated stable disease, including an early clinical signal in an HPV-positive head and neck squamous cell carcinoma [1].
- ABOYA-119 Trial: The Phase 1/2a trial of the ATR inhibitor ATRN-119 also showed early activity, with seven patients achieving stable disease, including three patients in the 550 mg twice daily cohort showing tumor shrinkage of 7%, 14%, and 21% [1].

Aprea plans to refine dosing strategies and explore combination therapies to address unmet medical needs in cancer treatments. The company expects to submit an abstract to a major oncology conference and may evaluate APR-1051 in combination with checkpoint inhibitors [1].

References:
[1] https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-reports-second-quarter-2025-financial-results